Emilio Torres

Categories: | | | | | | | |
ELZA at ESCRS 2026, Monday in London
Mini-scleral lenses cut higher-order aberrations by 97% in keratoconus, ELZA reported on Monday in London, alongside the ESCRS Research Workshop chaired by Prof. Farhad Hafezi.

READ

Categories: | | | | | |
ELZA at ESCRS 2026, Sunday in London
Ten-year cross-linking data, a case series of central toxic keratopathy and laboratory work on ring segments made Sunday ELZA’s busiest day at ESCRS 2026 in London.

READ

Categories: | | | | | |
ELZA at ESCRS 2026, Saturday in London
Corneal biomechanics ran through ELZA’s Saturday in London, from a didactic course talk to data showing that more than 30% of the children of keratoconus patients already have measurable corneal abnormalities.

READ

Categories: | | | | |
ELZA at ESCRS 2026, Friday in London
The ESCRS 2026 Cornea Day opened ELZA’s congress in London. Prof. Farhad Hafezi co-chaired the keratoconus session, and Dr Emilio Torres-Netto argued that cross-linking can improve vision, not only halt disease.

READ

Categories: | | |
ELZA at SOG 2026 in Lausanne, keratoconus consensus and corneal biomechanics
At the 119th SOG annual congress in Lausanne, Prof. Farhad Hafezi chaired the ESCRS session on the second global keratoconus consensus, and Dr. Emilio Torres-Netto spoke on corneal biomechanics as a tool for clinical decision-making.

READ

Categories: | | | | | | |
ELZA at ESCRS 2026 in London
The ELZA Institute travels to the 44th ESCRS Congress at ExCeL London, 11 to 15 September 2026, with seven podium presentations, nine invited lectures, six chaired sessions and six e-posters. The programme spans ten-year cross-linking outcomes, customised ELZA-PACE, ECO-CAIRS ring segments and keratoconus screening.

READ

Categories: | |
Oral riboflavin and sunlight did not stiffen corneas in a new rabbit study
Swapping the UV lamp for the sun and riboflavin drops for a vitamin B2 tablet is being promoted as a low-cost keratoconus treatment. A new ELZA study in the Journal of Refractive Surgery tested it in living eyes and found no corneal stiffening at all.

READ

Categories: | | | | | | |
Second-generation sub400 cross-linking for ultra-thin keratoconus corneas published
ELZA researchers report 12-month outcomes for a second-generation sub400 cross-linking protocol that extends CXL to ultra-thin keratoconus and post-LASIK ectasia corneas below 400 micrometres, halting progression in 76% of eyes while shortening treatment to about 18 minutes.

READ

Categories: | | |
World Keratoconus Congress 2026 in Florence
Insights from ELZA’s contributions to the World Keratoconus Congress 2026 in Florence – ELZA PACE, CXL innovation, and personalised keratoconus treatment strategies

READ

Categories: | | |
High-dose riboflavin and sunlight CXL?
Can sunlight and riboflavin (vitamin B2) treat keratoconus? New publication explains why current evidence does not support it.

READ

Load More
.
.